Verosudil (AR-12286) is a drug which acts as a potent and selective inhibitor of the enzyme Rho kinase, and has been investigated for the treatment of glaucoma.[1][2]
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H17N3O2S |
Molar mass | 327.40 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Williams RD, Novack GD, van Haarlem T, Kopczynski C (November 2011). "Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension". American Journal of Ophthalmology. 152 (5): 834–41.e1. doi:10.1016/j.ajo.2011.04.012. PMID 21794845.
- ^ Skaat A, Jasien JV, Ritch R (September 2016). "Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma". Journal of Glaucoma. 25 (9): e807-14. doi:10.1097/IJG.0000000000000508. PMID 27552517. S2CID 2663391.